Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treamid for Persistent Lung Damage and Reduced Exercise Tolerance After COVID-19
NCT05516550Phase 3Unknown
- Sponsor
- PHARMENTERPRISES LLC
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of treamid in post-COVID-19 condition (PCC), pulmonary fibrosis (PF), sponsored by PHARMENTERPRISES LLC. Status: unknown.
02
Drugs
treamid
03
Conditions
post-COVID-19 condition (PCC)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT05516550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516550.